Bellerophon Therapeutics jumps on China commercialization deal

Bellerophon Therapeutics

05/01/2023 16:09

** Drug developer Bellerophon Therapeutics Inc's  BLPH.O 
shares more than double to $2.15, top pct gainer across U.S.
exchanges
    ** Company's shares set for biggest one day pct gain in more
than two years, if gains hold
    ** BLPH says it has entered into a licensing and
commercialization deal in Greater China for INOpulse with Baylor
BioSciences
    ** Bellerophon to receive license payment of $6 mln and is
entitled to royalties of 5% on net sales from all of the
licensed INOpulse indications within Greater China
    ** Baylor BioSciences will receive exclusive rights to
develop and commercialize the product within Greater China
    ** INOpulse delivery system is being developed for treatment
of patients with pulmonary hypertension associated with
interstitial lung disease
    ** Bellerophon shares fell ~71% last year
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com))